Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.67 --0%
EPS Growth %: -133.3%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
IMPP, RH, YB, More
EPS Growth %: -133.3%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
IMPP, RH, YB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of $0.02, versus ($0.04) reported last year. Revenue for the quarter came in at $3.8 million, versus $1.8 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
- American Eagle Outfitters (AEO) Tops Q2 EPS by 57c
- Qifu Technology (QFIN) PT Lowered to $11 at BofA Securities
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
